2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alexey Danilov, MD, PhD, discusses the significance of a manuscript that was published following the first Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
“This manuscript summarizes the findings [from] a meeting of experts in leukemia, lymphoma, and multiple myeloma, who discussed and highlighted advances in these key areas, as well as unmet needs and unanswered questions.”
Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discussed the significance of a manuscript on challenges and emerging approaches for the management of patients with lymphoma that was published following the first Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
The manuscript highlighted notable advances in the 3 disease areas, as well as unmet needs and unanswered questions, which were informed by discussions from the meeting, Danilov said. The field has access to published guidelines from multiple entities in the respective fields, including the National Comprehensive Cancer Network, he added. However, these guidelines primarily include preexisting evidence and do not address the controversies that are faced in clinical practice, he noted. During the meeting, investigators discussed some of these controversies and proposed solutions to them, Danilov said.
The manuscript included treatment selection and sequencing considerations for patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). In the MCL section, the manuscript authors focused on chemotherapy-free frontline therapy, the evolving role of autologous stem cell transplant as a consolidation strategy, treatment sequencing for patients with relapsed disease, and approaches for patients with high-risk disease.
The CLL portion shed light on considerations when selecting a continuous vs fixed-duration therapy in the first-line setting, treatment for high-risk CLL, how to select an appropriate BTK inhibitor, and treatment approaches for patients with double-refractory disease. In terms of DLBCL, the investigators covered the role of polatuzumab vedotin-piiq (Polivy) in the frontline setting, the selection and sequencing of CAR T-cell therapies and bispecific antibodies, sequencing these agents with other therapies, and treatment after CAR T-cell therapy.
In their discussion, the manuscript authors noted that the meeting will reconvene later in 2025 to identify best practices and consensus recommendations for disputed topics.
Related Content: